DK1060749T3 - Vandigt farmaceutisk præparat indeholdende Tezosentan - Google Patents

Vandigt farmaceutisk præparat indeholdende Tezosentan

Info

Publication number
DK1060749T3
DK1060749T3 DK00110425T DK00110425T DK1060749T3 DK 1060749 T3 DK1060749 T3 DK 1060749T3 DK 00110425 T DK00110425 T DK 00110425T DK 00110425 T DK00110425 T DK 00110425T DK 1060749 T3 DK1060749 T3 DK 1060749T3
Authority
DK
Denmark
Prior art keywords
tezosentan
pharmaceutical preparation
preparation containing
aqueous pharmaceutical
aqueous
Prior art date
Application number
DK00110425T
Other languages
Danish (da)
English (en)
Inventor
Peter Dr Actelion Pha Loeliger
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26070369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1060749(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK1060749T3 publication Critical patent/DK1060749T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK00110425T 1999-05-22 2000-05-16 Vandigt farmaceutisk præparat indeholdende Tezosentan DK1060749T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP9903532 1999-05-22
US09/573,504 US6316453B1 (en) 1999-05-22 2000-05-18 Aqueous pharmaceutical composition

Publications (1)

Publication Number Publication Date
DK1060749T3 true DK1060749T3 (da) 2003-06-23

Family

ID=26070369

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00110425T DK1060749T3 (da) 1999-05-22 2000-05-16 Vandigt farmaceutisk præparat indeholdende Tezosentan

Country Status (12)

Country Link
US (1) US6316453B1 (ja)
EP (1) EP1060749B1 (ja)
JP (1) JP4632385B2 (ja)
AR (1) AR057123A1 (ja)
AT (1) ATE235255T1 (ja)
CA (1) CA2308660C (ja)
DE (1) DE60001768T2 (ja)
DK (1) DK1060749T3 (ja)
ES (1) ES2195818T3 (ja)
NZ (1) NZ504671A (ja)
PT (1) PT1060749E (ja)
ZA (1) ZA200002318B (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528065B2 (en) * 2006-01-17 2009-05-05 International Business Machines Corporation Structure and method for MOSFET gate electrode landing pad

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW313568B (ja) * 1994-12-20 1997-08-21 Hoffmann La Roche
DK0897914T3 (da) * 1997-08-19 2004-09-27 Hoffmann La Roche Fremgangsmåde til fremstilling af 2,5-disubstituerede pyridiner

Also Published As

Publication number Publication date
CA2308660C (en) 2008-08-12
DE60001768D1 (de) 2003-04-30
US6316453B1 (en) 2001-11-13
CA2308660A1 (en) 2000-11-22
PT1060749E (pt) 2003-08-29
ES2195818T3 (es) 2003-12-16
JP2001002564A (ja) 2001-01-09
JP4632385B2 (ja) 2011-02-16
ATE235255T1 (de) 2003-04-15
NZ504671A (en) 2001-11-30
EP1060749B1 (en) 2003-03-26
DE60001768T2 (de) 2003-10-16
ZA200002318B (en) 2000-11-16
AR057123A1 (es) 2007-11-14
EP1060749A1 (en) 2000-12-20

Similar Documents

Publication Publication Date Title
NO20015175D0 (no) Farmasöytisk sammensetning
NO20071303L (no) Farmasoytiske preparater
EE05063B1 (et) Bensamiididerivaati sisaldav farmatseutiline preparaat
EE05376B1 (et) Vesisuspensioonip?hineÁparenteraalneÁravimpreparaatÁjaÁsedaÁsisaldavÁviaal
NO20020086L (no) Smaksmaskerte farmasöytiske flytende formuleringer
DK1466615T3 (da) Farmaceutisk præparat
NO20015670L (no) Forbedrede farmasöytiske formuleringer
PT1210085E (pt) Solucoes farmaceuticas de levosimendano
NO20015149D0 (no) Nytt farmasöytisk preparat
NO20022606L (no) Farmasöytiske kombinasjoner
NO20014926L (no) Farmasöytiske forbindelser
NO20015148D0 (no) Nytt farmasöytisk preparat
EE200200073A (et) Bensamiididerivaati sisaldav farmatseutiline preparaat
DK1227817T3 (da) Ciclesonid-holdigt vandigt farmaceutisk præparat
FI4488U1 (fi) Farmaseuttinen koostumus
ID30397A (id) Larutan oral prukaloprida
NO20015104D0 (no) Nytt farmasöytisk preparat
NO20016430L (no) Farmasöytisk kompleks
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20015105L (no) Nytt farmasöytisk preparat
NO20004816D0 (no) Ny farmasøytisk formulering
NO20032957D0 (no) Farmasöytisk emulsjonspreparat
NO20021036D0 (no) Farmasöytisk preparat
DK1060749T3 (da) Vandigt farmaceutisk præparat indeholdende Tezosentan
DE50008261D1 (de) Retardierte darreichungsform enthaltend tramadolsaccharinat